Medinova AG   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Northwood United Kingdom (1997)
Status: Acquired by ICON (2019)

Organization Overview

First Clinical Trial
2007
NCT01125410
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (2)

dequalinium dichloride (2 trials)

urea (2 trials)

Drugs in Phase 3 Trials (3)

clindamycin (cleocin) (1 trial)

lactisal (1 trial)

mucopolysaccharide polysulphate (1 trial)

Drugs in Phase 1 Trials (1)

gynatren (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophic Vaginitis (Phase 1)

Atrophy (Phase 1)

Candidiasis (Phase 4)

Candidiasis, Vulvovaginal (Phase 4)

Phlebitis (Phase 3)

Thrombophlebitis (Phase 3)

Vaginal Diseases (Phase 3)

Vaginitis (Phase 1)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6